The correlation of membranous glycoprotein-gp-170, cytoplasmic glutathione and glucose-6-phosphate dehydrogenase levels with multidrug resistance in transitional cell carcinoma cell lines of the urinary tract

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 727-731

  Yu, Dah Shyong ^a   Chang, Sun Yran ^a   Ma, Cheng Ping ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

glucose 6 phosphate dehydrogenase; glutathione; glycoprotein gp 170; multidrug resistance; transitional cell carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLYCOPROTEIN GP 160; METHOTREXATE; THIOTEPA; VINBLASTINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; UROTHELIUM;

EID: 0031012644     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65259-5     Document Type: Article

References (32)

1. Scher, H. I. and Sternberg, C. N.: Chemotherapy of urologic malignancies. Semin. Urol., 3: 329, 1985.
2. Shoemaker, R. H., Curt, G. A. and Carney, D. N.: Evidence for multidrug resistant cells in human tumor cell populations. Cancer Treat Rep., 67: 883, 1983.
3. Dalton, W. S., Durie, B. G. M., Alverto, D. S., Gerlack, J. H. and Cress, A. E.: Characterization of a new drug-resistant human myeloma cell line that express p-glycoprotein. Cancer Res., 46: 5125, 1986.
4. Fojo, A., Hamilton, I. C., Young, R. E. and Ozoles, R. F.: Multidrug resistance in ovarian cancer. Cancer, 60: 2075, 1987.
5. Mirski, S. E. L., Gerlach, J. H. and Cole, S. P. C.: Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res., 47: 2594, 1987.
6. Mickisch, G. H., Kossig, J., Keilhauer, G. K., Schlick, E., Tschada, R. and Alken, P. M.: Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res., 50: 3670, 1990.
7. Sherwood, S. W., Assaraf, Y. G., Molina, A. and Schimke, R. T.: Flow cytometric characterization of antifolate resistance in cultured mammalian cells using fluoresceinated methotrexate and daunorubicin. Cancer Res., 50: 4946, 1990.
8. Parris, C. N., Claire Walker, M., Masters, J. R. W. and Arlett, C. F.: Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. Cancer Res., 50: 7513, 1990.
9. Kartner, N., Evernden-Porelle, D., Bradley, G. and Ling, V.: Detection of p-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316: 820, 1985.
10. Gottesman, M. M. and Pastan, I.: The multidrug transporter, a double-edged sword. J. Biol. Chem., 263: 1263, 1988.
11. Benson, M. C., Giella, J., Whang, I. S., Buttyan, R., Hensle, T. W., Karp, F. and Olsson, C. A.: Flow cytometric determination of the multidrug resistance phenotype in transitional cell cancer of the bladder: implications and applications. J. Urol., 146: 982, 1991.
12. Gottesman, M. M.: How cancer cells evade chemotherapy. Cancer Res., 53: 747, 1993.
13. Mickisch, G. H., Roehrich, K., Koessig, J., Forster, S., Tschada, R. K. and Alken, P. M.: Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J. Urol., 144: 755, 1990.
14. Ahn, H., Lee, E., Kim, K. and Lee, C.: Effect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines. J. Urol., 151: 263, 1994.
15. Volm, M., Kastel, M., Mattern, J. and Efferth, T.: Expression of resistance factors (p-glycoprotein, glutathione S-transferase-π, and topoisomerase II) and their interrelationship to protooncogene products in renal cell carcinomas. Cancer, 71: 3981, 1993.
16. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J. L. M., Scheper, R. J. and Zaman, G. J. R.: Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557, 1994.
17. Mostifi, F. K., Sorbin, L. H., Torloni, H.: Histological typing of urinary bladder tumors. In International Classification of Tumors. World Health Organization, No. 10, Geneva, 1973.
18. Marshall, V. F.: The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms. J. Urol., 68: 714, 1952.
19. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D. and Michell, J. B.: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936, 1987.
20. Yu, D. S., Chang, S. Y. and Ma, C. P.: The effect of methylene blue-sensitized photodynamic treatment on bladder cancer cells: a further study on flow cytometric basis. J. Urol., 149: 1198, 1993.
21. Loken, M. R., Sweet, R. G. and Herzenberg, L. A.: Cell discrimination by multiangle light scattering. J. Histochem. Cytochem., 24: 284, 1976.
22. Tietze, F.: Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Anal. Biochem., 27: 502, 1969.
23. Lohr, G. W., Waller, H. D.: Glucose-6-phosphate dehydrogenase. In Methods of Enzymatic Analysis. H. U. Bergmeyer, ed., Academic Press, New York, 1974, p. 636.
24. Harris, D. T.: Hormonal therapy and chemotherapy of renal cell carcinoma. Semin. Oncol., 10: 422, 1983.
25. Berry, J. and MacDonald, R. N.: Cisplatinum, cyclophosphamide, and prednisolone therapy for stage D prostatic cancer. Cancer Treat Rep., 66: 1403, 1982.
26. Herr, H. W., Laudone, V. P. and Whitmore, W. F.: An overview of intravesical therapy for superficial bladder tumors. J. Urol., 138: 1363, 1987.
27. Sternberg, C. N., Yagoda, A. and Scher, H. I.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol., 133: 403, 1985.
28. Morrow, C. S. and Cowan, K. H.: Mechanisms and clinical significance of multidrug resistance. Oncology, 2: 55, 1988.
29. Mickisch, G., Bier, H., Bergler, W., Bak, M., Tschada, R. and Alken, P.: P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary renal cell carcinomas. Urol. Intern., 45: 170, 1990.
30. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pasten, I. and Willingham, M. C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci., 84: 7735, 1987.
31. Kramer, R. A., Zakher, J. and Kim, G.: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science, 241: 694, 1988.
32. Bellamy, W. T., Dalton, W. S., Meltzer, P. and Dorr, R. T.: Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. Biochem. Pharmacol., 38: 787, 1989.